Talk to your doctor or Registered Dietitian about your risk factors, blood test results, and diet to see if these supplements are right for you.
In addition, liraglutide is a short-acting GLP-1 agonist, with subcutaneous dose of 1.25-1.9 mg per day, based on the pharmacokinetics results in rabbit, the inventors concluded that the drug concentration up to 50 mg/mL have to be used, with 2-4 doses per day, the frequent nasal dosing will potentially result in toxic effects, as well as poor patient compliance
Tirzepatide is commonly discussed as a dual GIP and GLP-1 receptor agonist, while Retatrutide is commonly discussed as a triple GIP, GLP-1 and glucagon receptor agonist
Several recent CVOTs have shown that GLP-1RAs can reduce the decline of estimated GFR (eGFR) and delay the onset of the occurrence of proteinuria in patients with T2DM [4, 22, 26, 46, 47]